“…EH cure models may be helpful when cure is plausible and likely to result in less extrapolation variability. HIGHLIGHTS: In health economic modeling, to help anchor long-term survival extrapolation, it has been recommended that survival models incorporate background mortality rates using excess hazard (EH) methods. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: Individuals from the Hoorn Diabetes Care System cohort (N = 15,392) were filtered to satisfy trial inclusion criteria (including EMPA-REG, CANVAS, and DECLARE-TIMI58) or satisfy the current Dutch reimbursement criteria for SGLT2i. We validated a health economic model (MICADO) by comparing simulated and observed outcomes regarding the relative risks of events in the intervention and comparator arm from three trials, and used the validated model to evaluate the long-term health outcomes using the filtered cohorts’ baseline characteristics and treatment effects from trials and a review of observational studies. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A mixed-methods implementation and process evaluation will examine factors that influence implementation, and a health economic evaluation will assess the cost-effectiveness of the intervention. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Hydroxyurea is the only disease-modifying therapy with proven feasibility and efficacy suitable for SSA; however, no one has quantified the health economic implications of its use. Therefore, from the perspective of the health care provider, we estimated the incremental cost-effectiveness of hydroxyurea as a fixed-dose regimen or maximum tolerated dose (MTD) regimen, versus SCA care without hydroxyurea. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Individuals who survive sepsis are at high risk of chronic sequelae, resulting in significant health-economic costs. Several studies have focused on aspects of healthcare pathways of sepsis survivors but comprehensive, longitudinal overview of their pathways of care are scarce. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Secondary outcomes include the number and duration of outbreaks and home closures. Health economic and modelling analyses will investigate the cost-effectiveness and cost consequences of the testing intervention. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This trial will provide efficacy, safety and health economic data on serial ketamine infusions and thus help inform clinical practice on the potential role of this treatment in the management of depression. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: We conducted a US-based health economic analysis of AF screening using patient-level data from mSToPS. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Data obtained during the trial will be used for later health-economic evaluations. The trial architecture involves a central statistical unit, an independent monitoring institute, and a data safety monitoring board. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: We compared the health, economic, and financial consequences of introducing the two vaccines in 72 GAVI-eligible countries using a number of different outcome measures to evaluate affordability, cost-effectiveness, and distributional equity. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In addition, we used the World Health Organization Health Economic Assessment Tool (HEAT) to calculate benefits of increased physical activity if 50% of short trips were made by bicycle. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Direct process costs from the health care providers' perspective were estimated according to the German DRG calculation framework. The health economic evaluation was based on margiual cost-effectveness ratios (MCERs); an individual marginal cost effectiveness relation ≤ 100 € per % WOMAC index increase was considered as primary endpoint of the confirmatory cohort comparison. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A process-oriented retrospective online survey will examine health professionals’ attitudes toward TFGT; a health economic analysis will determine the cost effectiveness of the intervention. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We conducted a systematic literature review and mixed-treatment-comparison (MTC) meta-analysis of available data from randomized controlled trials (RCTs) to derive estimates of efficacy for 8 classes of treatments for HMB, to inform health-economic analysis and future studies. METHODS: A systematic review identified RCTs that reported data on menstrual blood loss (MBL) at baseline and one or more follow-up times. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We searched the major bibliographic databases in August 2013 to identify articles that focused primarily on students’ knowledge, skills, satisfaction and attitudes toward eLearning, and health economic information and adverse effects as secondary outcomes. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Secondary analyses will be performed according to the ITT principle. In health economic evaluations, we will estimate the incremental cost-effectiveness ratios. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS/DESIGN: Design: Primary care-based 3-arm randomized controlled trial with 12-month follow-up and health economic and qualitative evaluations. Participants: Less active 45–75 year olds (n = 993) will be recruited by post from six South West London general practices, maximum of two per household and households randomised into three groups. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Target recruitment is 1000 participants. Health economic analysis is also planned. DISCUSSION: The results of PROGNOSIS will provide the most comprehensive evidence to date on the accuracy of the sFlt-1/PlGF ratio for short-term prediction of preeclampsia/eclampsia/HELLP syndrome. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Key secondary outcomes are patients’ symptom burden, place of death and survival, and health economic aspects. Subgroup analysis will assess results according to cancer type, age, early vs not early SPC, site of care, and setting. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Clinical trials for treatments indicated for orphan diseases may be limited due to the low prevalence of such diseases; this can result in implications for both regulatory and health economic perspectives. This study assessed the pivotal clinical evidence packages submitted to support applications for European Medicines Agency (EMA) marketing authorizations for treatments for orphan conditions, in relation to the size of the eligible patient population. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso